

A. Sites of Major M4N Accumulation
IV
IP
M4N (ug/g)
0
5
10
15
20
Sm Intestine
Liver
Stomach
Caecum
Organ La Intestine
Fat
Organ
B. Sites of Minor M4N Accumulation
IV
IP
M4N (ug/g)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
Brain
Kidney
Blood
Heart
Spleen
Organ

Figure 1



Mouse A - 4 Hours
Mouse B - 6 Hours
Mouse C - 18 Hours
Mouse D - 18 Hours
Mouse E - 6 Days
Mouse F - 6 Days
33000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
M4N (ng/g)
Sm Intestine
Lg Intestine
Stomach
Caecum
Tumor
Heart
Kidney
Lungs
Brain
Spleen
Liver
Fat
Organ

Figure 2

Figure 3





A. Control Vs. M4N-Treated Male Mice
Body Weight (g)
Day
M4N
Control
0
5
10
15
20
25
30
0
20
40
60
80
100
120
B. Control Vs. M4N-Treated Female Mice
Body Weight (g)
Day
M4N
Control

Figure 4



* = p-value ≤ 0.05; Student's two-tailed T-test

Figure 5


TA in DMSO - Serum Results
TA
14000
12000
10000
8000
6000
4000
2000
0
0
2
4
6
8
10
12
14
16
Timepoint (hr)
10 mg/kg male
50 mg/kg female
50 mg/kg male
100mg/kg female
100 mg/kg male
10 mg/kg female



Delivery
Intranasal
Intravenous
Intra-Arterial (w/wo OD)
Inhalation
Oral
Parental (SC, IP, IM)
Intra-Ventricular Or Intra-Cranial
Form
Solution
Emulsion
Liposome
Nanoparticle
Polymer Implant
M_4N
G_4N

FIG. 6


Delivery
Intranasal
Intravenous
Intra-Arterial
Inhalation
Oral
Parental (SC, IP, IM)
Form
Solution
Emulsion
Liposome
Nanoparticle
Polymer
M_4N
G_4N

FIG. 7